Shimabukuro 2011.

Methods	4‐Week wash‐out dietary baseline stabilisation period 4‐Week before‐and‐after trial
Participants	15 individuals with type 2 diabetes and hypercholesterolaemia aged 30 to 79 years; TC ≥ 220 mg/dL, TG 150 to 350 mg/dL Exclusion criteria: statin hypersensitivity, hepatic dysfunction, renal dysfunction, pregnancy, poorly controlled diabetes, recent stroke, CHD, congestive heart failure, FH, secondary hyperlipidaemia Atorvastatin baseline TC: 6.58 mmol/L (254 mg/dL) Atorvastatin baseline LDL‐C: 4.23 mmol/L (164 mg/dL) Atorvastatin baseline HDL‐C: 1.42 mmol/L (55 mg/dL) Atorvastatin baseline TG: 1.96 mmol/L (174 mg/dL)
Interventions	Atorvastatin 10 mg/d Pitavastatin 2 mg/d
Outcomes	Per cent change from baseline at 4 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	Atorvastatin group was analysed                 SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Unclear risk	No source of funding was provided